DR4 Polyclonal antibody

• Featured Product
• KD/KO Validated

DR4 Polyclonal Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, ELISA

Conjugate

Unconjugated

Publications

10

Cat no : 24063-1-AP

Synonyms

APO2, CD261, Death receptor 4, DR4, TNFRSF10A, TRAIL R1, TRAIL receptor 1, TRAILR 1, TRAILR1

---

Validation Data Gallery

• 

  WB analysis using 24063-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 24063-1-AP (DR4 antibody) at dilution of 1:6000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of Jurkat using 24063-1-AP

  Jurkat cells were subjected to SDS PAGE followed by western blot with 24063-1-AP (DR4 antibody) at dilution of 1:800 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HeLa using 24063-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 24063-1-AP (DR4 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of Jurkat using 24063-1-AP

  Jurkat cells were subjected to SDS PAGE followed by western blot with 24063-1-AP (DR4 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

---

Tested Applications

• Positive WB detected in: A549 cells, Jurkat cells, HeLa cells, PC-3 cells

Recommended dilution

• Western Blot (WB): WB : 1:2000-1:12000

Sample-dependent, check data in validation data gallery

Published Applications

• KD/KO: See 2 publications below
• WB: See 10 publications below

Product Information

The immunogen of 24063-1-AP is DR4 Fusion Protein expressed in E. coli.

• Tested Reactivity: human
• Cited Reactivity: human
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: DR4 fusion protein Ag20927
• Full Name: tumor necrosis factor receptor superfamily, member 10a
• Calculated molecular weight: 50 kDa
• Observed molecular weight: 37-55 kDa
• GenBank accession number: BC012866
• Gene symbol: TNFRSF10A
• Gene ID (NCBI): 8797
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily. TRAIL activates apoptosis through the death receptors DR4 (also known as TRAILR1 and TNFRSF10A) and DR5 (also known as TRAILR2, KILLER and TNFRSF10B). DR4 and DR5 are single-pass type I membrane proteins that contain intracellular death domains (DD) and upon activation mediate apoptotic signals (PMID: 11163110). Binding of TRAIL to DR4 or DR5 results in receptor oligomerization and recruitment of FAS-associated protein with death domain (FADD) and caspase 8 to form a functional death-inducing signalling complex (DISC). Upon DISC formation, caspase 8 is cleaved and activated, which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis (PMID: 18813321). DR4 or DR5 promotes the activation of NF-kappa-B and play an important role in inflammation (PMID: 9430227, 19434100).

Publications

Species	Application	Title
human	WB	Cell Death Dis; Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study.; Authors - H-Y Li
human	WB	Am J Cancer Res; PMID: 31598394; Authors - Ran An
human	WB	Biomed Pharmacother; Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.; Authors - Juan Yang
human	WB	Oncogenesis; JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells.; Authors - Q Wang
human	WB	Mar Drugs; Fucoidan Induces Apoptosis of HT-29 Cells via the Activation of DR4 and Mitochondrial Pathway.; Authors - Xu Bai
human	WB	J Ethnopharmacol; Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis.; Authors - Xingkang Wu

Related Products

DR5-Specific Polyclonal antibody

15497-1-AP

TRAIL Polyclonal antibody

17235-1-AP

FADD Polyclonal antibody

14906-1-AP

Caspase 8/p43/p18 Polyclonal antibody

13423-1-AP

NF-κB p65 Polyclonal antibody

10745-1-AP